Observational studyBMC cardiovascular disorders2026
Cardiovascular disease risk factors in women with O-desmethylangolensin producing and non-producing gut microbial metabotypes: an observational study.
Observational study in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDaidzein, an isoflavone in soy, is metabolized to O-desmethylangolensin (ODMA) by select gut bacteria. Not all individuals have gut microbiomes capable of producing ODMA, resulting in ODMA producer and non-producer metabotypes. A limited body of research suggests that ODMA producers have lower systolic blood pressure, percent body fat and total cholesterol, compared to non-producers. More work is needed to confirm this relationship in other populations.
methodsData from the Study of Women's Health Across the Nation (SWAN), a study of women in their middle years, was used. A subset of women who reported consumption of isoflavones in diet or supplements was included for this analysis. Urinary ODMA and daidzein of 148 participants were measured via HPLC-MS-MS to classify metabotypes: ODMA (nmol/L)/daidzein (nmol/L) = 0, non-producers (n = 23); ODMA (nmol/L)/daidzein (nmol/L) > 0 but less than 0.5, low-producers (n = 90); and ODMA (nmol/L)/daidzein (nmol/L) > 0.5, high-producers (n = 35). Multivariable linear regression models were used to compare cardiovascular disease (CVD) risk markers among groups. Models were adjusted for age, race, self-reported health, blood pressure medication, smoking, menopausal status and anthropometry.
resultsODMA non-producers had higher systolic blood pressure (adj. mean difference = 7.6 mmHg, 95% CI: 1.1, 14.1, p = 0.02) compared to high producers. Another trend but not statistically significant difference observed included higher fasting serum glucose (adj. mean difference = 6.1 mg/dl, CI: -0.9, 13.2, p = 0.09) in ODMA non-producers when compared to ODMA producers.
conclusionsIn this diverse sample of U.S. women, this study observed higher blood pressure in ODMA non-producers than ODMA producers. This aligns with prior work associating ODMA producers with a more favorable CVD risk profile compared to non-producers, and provides additional evidence that this gut microbial metabotype may be related to cardiovascular health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.